Get the Stockscreener App
0.6551
5.17%
-0.0357
AIM ImmunoTech Inc stock is traded at $0.6551, with a volume of 254.05K.
It is down -5.17% in the last 24 hours and down -46.74% over the past month.
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
See More
Previous Close:
$0.6908
Open:
$0.699
24h Volume:
254.05K
Relative Volume:
0.20
Market Cap:
$2.61M
Revenue:
$202.00K
Net Income/Loss:
$-28.96M
P/E Ratio:
-1.0918
EPS:
-0.6
Net Cash Flow:
$-21.85M
1W Performance:
-33.83%
1M Performance:
-46.74%
6M Performance:
-73.56%
1Y Performance:
+398.67%
1-Day Range:
$0.6141
$0.7029
1-Week Range:
$0.6141
$0.98
52-Week Range:
$0.0632
$20.33
AIM ImmunoTech Inc Stock (AIM) Company Profile
Name
AIM ImmunoTech Inc
Sector
Industry
Phone
352 448 7797
Address
2117 SW Highway 484, Ocala, FL
Compare AIM vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
0.6551 | 2.75M | 202.00K | -28.96M | -21.85M | -0.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.70 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.45 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
721.77 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.03 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.37 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
AIM ImmunoTech Inc Stock (AIM) Latest News
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million - Bitget
AIM ImmunoTech (AIM) Projects $1.8M from Rights Offering - GuruFocus
Aim Immunotech Announces Expiration And Preliminary Results Of Its Rights Offering For Aggregate Gross Proceeds Of $1.8 Million - TradingView
AIM ImmunoTech raises $1.8M with $1,000 preferred stock and warrant bundles - Stock Titan
AIM ImmunoTech Signs Agreement for Planning of a Proposed - GlobeNewswire
AIM Collaborates with Thermo Fisher for Phase 3 Trial of Amplige - GuruFocus
AIM ImmunoTech Inc. has signed an agreement to plan a proposed Phase III clinical trial of its core candidate drug Ampligen for the treatment of advanced pancreatic cancer. - Bitget
Experimental pancreatic cancer drug Ampligen moves toward Phase 3 test - Stock Titan
AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer - Sahm
AIM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
AIM ImmunoTech (AIM) Updates Rights Offering Terms - GuruFocus
Investors get $1,000 AIM unit with 2,000 warrants — but clock is ticking - Stock Titan
AIM ImmunoTech (NYSE American: AIM) offers 12,000 Units and 24M warrants - Stock Titan
AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering - Sahm
AIM Should I Buy - Intellectia AI
AIM ImmunoTech (AIM) Extends Rights Offering Subscription Period - GuruFocus
AIM ImmunoTech Inc. recently announced that it will extend the exercise period for shareholder subscription rights in its previously announced stock offering plan. - Bitget
AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026 - The Manila Times
Aim Immunotech Announces Extension Of Subscription Period - TradingView
AIM cancer-drug investors get new March 3 deadline, use-it-or-lose-it rights - Stock Titan
AIM ImmunoTech advances Phase 2 pancreatic cancer trial with Ampligen and Imfinzi - Indian Pharma Post
AIM ImmunoTech (AIM) Reports Progress in Pancreatic Cancer Study - GuruFocus
AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer - Bitget
AIM ImmunoTech Announces Planned Milestones in the Ongoing - GlobeNewswire
New pancreatic cancer trial pairs AIM drug with AstraZeneca's Imfinzi - Stock Titan
AIM ImmunoTech at Virtual Investor Closing Bell: Strategic Focus on Pancreatic Cancer By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
AIM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Merger Talk: Will AIM ImmunoTech Inc. stock outperform global peersEarnings Beat & Verified Chart Pattern Trade Signals - mfd.ru
CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering - The Manila Times
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event - The Manila Times
Pancreatic cancer drug strategy: AIM ImmunoTech CEO in Feb. 19 live webcast - Stock Titan
AIM ImmunoTech at Corporate Connect: Ampligen’s Role in Pancreatic Cancer - Investing.com Canada
AIM: Ampligen demonstrates strong survival and quality of life benefits in late-stage pancreatic cancer - TradingView
AIM ImmunoTech launches rights offering to raise $12 million - Intellectia AI
AIM ImmunoTech Launches Rights Offering for Common Stock Holders - GuruFocus
Aim Immunotech Announces Commencement Of Rights Offering - TradingView
AIM ImmunoTech Announces Commencement of Rights Offering - GlobeNewswire
Cancer drug developer AIM ImmunoTech seeks $12M from shareholders - Stock Titan
ImmunoTech (AIM) updates S-1 with exhibits-only Amendment No. 3 - Stock Titan
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
AIM ImmunoTech to Participate in Corporate Connect Webinar - Intellectia AI
AIM ImmunoTech to Participate in the Corporate Connect - GlobeNewswire
AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - 富途牛牛
AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted ... - Herald and News
AIM ImmunoTech Eyes $12M Funding Boost with Rights Offering - timothysykes.com
AIM ImmunoTech Inc. (AIM) stock: surges as pancreatic cancer trial shows survival breakthrough - parameter.io
AIM ImmunoTech reports year-end positive phase 2 interim progress for Ampligen® (rintatolimod) plus AstraZeneca's Imfinzi® (durvalumab) in pancreatic cancer - marketscreener.com
AIM ImmunoTech reports data in year-end update from Phase 2 trial of Ampligen - TipRanks
AIM ImmunoTech Inc Stock (AIM) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):